Supplement 1

Admission albumin concentrations and response to nutritional therapy in hospitalized patients at malnutrition risk: secondary analysis of a randomized clinical trial

Brief title: Admission albumin concentrations and nutritional therapy

Céline Bretscher, MD; Fabienne Boesiger, MD; Nina Kaegi-Braun, MD; Lara Hersberger, MD; Prof Dileep N.Lobo, MD; David C.Evans, MD, Pascal Tribolet; Filomena Gomes, PhD; Claus Hoess, MD; Vojtech Pavlicek, MD; Stefan Bilz, MD; Sarah Sigrist, MD; Prof Michael Brändle, MD; Prof Christoph Henzen, MD; Robert Thomann, MD; Prof Jonas Rutishauser, PhD; Prof Drahomir Aujesky, MD; Prof Nicolas Rodondi, MD; Jacques Donzé, MD; Prof Zeno Stanga, MD; Prof Beat Mueller, MD; and Prof Philipp Schuetz, MD, MPH

Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland (Bretscher, Boesiger, Kaegi-Braun, Hersberger, Schuetz, Mueller); **Gastrointestinal Surgery, Nottingham Digestive Diseases Centre, National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Queen's Medical Centre, Nottingham, UK** (Lobo); **Trauma / Critical Care Surgery, OhioHealth Grant Medical Center, Columbus, Ohio, USA** (Evans); **Department of Health Professions, Bern University of Applied Sciences, Bern, Switzerland** (Tribolet); **The New York Academy of Sciences, New York, NY, USA** (Gomes); **Internal Medicine, Kantonsspital Münsterlingen, Münsterlingen, Switzerland** (Hoess, Pavlicek); **Internal Medicine and Endocrinology, Kantonsspital St Gallen, St Gallen, Switzerland** (Bilz, Sigrist, Brändle); **Internal Medicine, Kantonsspital Luzern, Luzern, Switzerland** (Henzen); **Internal Medicine, Bürgerspital Solothurn, Solothurn, Switzerland** (Thomann); **Internal Medicine, Kantonsspital Baselland, Standort Bruderholz Switzerland** (Rutishauser); **Department of General Internal Medicine** (Aujesky, Rodondi, Donzé) **and Division of Diabetology, Endocrinology, Nutritional Medicine, and Metabolism** (Stanga), **Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Medical Faculty of the University of Basel, Basel, Switzerland** (Schuetz, Mueller); **Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland** (Rodondi); **Division of General Internal Medicine, Brigham and Women's Hospital, Boston, MA, USA** (Donzé)

eTable 1:. Baseline Characteristics overall and stratified by CRP level

	overall	CRP <100 mg/L	CRP >100 mg/L	p-value
n	1389	970	401	
Sociodemographics				
Male sex	747 (53.8%)	510 (52.6%)	226 (56.4%)	0.2
Age				
mean (SD)	73.1 (13.5)	73.5 (13.6)	72.2 (13.2)	0.10
Age groups				**0.02**
< 65 years	220 (15.8%)	149 (15.4%)	67 (16.7%)	
65-75 years	468 (33.7%)	311 (32.1%)	155 (38.7%)	
> 75 years	701 (50.5%)	510 (52.6%)	179 (44.6%)	
Nutritional assessment				
Mean body-mass index (kg/m2), mean (SD)	24.6 (5.3)	24.4 (5.3)	25.1 (5.2)	**0.019**
Mean body-weight (kg), median (IQR)	68.5 (58.4-81.5)	67.1 (57.5-80.7)	71.0 (61.0-83.0)	**0.005**
NRS 2002 Score				<0.001
3 points	397 (28.6%)	311 (32.1%)	81 (20.2%)	
4 points	547 (39.4%)	376 (38.8%)	164 (40.9%)	
≥ 5 points	445 (32.0%)	283 (29.2%)	156 (38.9%)	
Weight loss, n (%)				**0.00**
≤ 5% in 3 months	679 (48.9%)	449 (46.3%)	225 (56.1%)	
> 5% in 3 months	226 (16.3%)	156 (16.1%)	65 (16.2%)	
> 5% in 2 months	186 (13.4%)	145 (14.9%)	37 (9.2%)	
> 5% in 1 month	298 (21.5%)	220 (22.7%)	74 (18.5%)	
Loss of appetite, n (%)	1242 (89.4%)	864 (89.1%)	364 (90.8%)	0.35
Food intake of normal requirement in the past week, n (%)				0.13
> 75%	130 (9.4%)	88 (9.1%)	38 (9.5%)	
50-75%	430 (31.0%)	319 (32.9%)	107 (26.7%)	
25-50%	581 (41.8%)	398 (41.0%)	175 (43.6%)	
< 25%	248 (17.9%)	165 (17.0%)	81 (20.2%)	
Severity of illness, n (%)				<0.001
very mild	30 (2.2%)	26 (2.7%)	4 (1.0%)	
mild	924 (66.5%)	714 (73.6%)	197 (49.1%)	
moderate	418 (30.1%)	224 (23.1%)	190 (47.4%)	
severe	17 (1.2%)	6 (0.6%)	10 (2.5%)	
Laboratory measurements				
Admission Abumin level (g/L), mean (SD)	30.2 (6.7)	31.9 (6.3)	26.1 (5.9)	**<0.001**
Admission CRP level (mg/L), median (IQR)	37 (9.4-117)	17 (5-42)	164.7 (130-223)	**<0.001**
Main admission diagnosis				
Cardiovascular desease, n (%)	154 (11.1%)	143 (14.7%)	8 (2.0%)	**<0.001**
Infection, n (%)	390 (28.1%)	166 (17.1%)	221 (55.1%)	**<0.001**
Cancer, n (%)	287 (20.7%)	195 (20.1%)	87 (21.7%)	0.51
Pulmonary disease, n (%)	84 (6.0%)	64 (6.6%)	19 (4.7%)	0.19
Frailty, n (%)	128 (9.2%)	107 (11.0%)	20 (5.0%)	**<0.001**
Other, n (%)	249 (17.9%)	214 (22.1%)	30 (7.5%)	**<0.001**
Comorbidities				
Coronary heart disease, n (%)	391 (28.1%)	286 (29.5%)	98 (24.4%)	0.06
Congestive heart failure, n (%)	249 (17.9%)	193 (19.9%)	53 (13.2%)	**0.003**
Hypertension, n (%)	753 (54.2%)	528 (54.4%)	215 (53.6%)	0.78
Cerebrovascular disease, n (%)	105 (7.6%)	72 (7.4%)	33 (8.2%)	0.61
Peripheral arterial disease, n (%)	132 (9.5%)	97 (10.0%)	32 (8.0%)	0.24
Chronic kidney disease, n (%)	453 (32.6%)	323 (33.3%)	123 (30.7%)	0.35
Diabetes, n (%)	303 (21.8%)	207 (21.3%)	91 (22.7%)	0.58
COPD, n (%)	195 (14.0%)	140 (14.4%)	55 (13.7%)	0.73
Dementia, n (%)	57 (4.1%)	45 (4.6%)	12 (3.0%)	0.16
Malignant disease, n (%)	496 (35.7%)	321 (33.1%)	169 (42.1%)	**0.001**

eTable 2:. Baseline Characteristics overall and stratified by Randomisation

	overall	Control	Intervention	p-value
n	1389	701	688	
Sociodemographics				
Male sex	747 (53.8%)	380 (54.2%)	367 (53.3%)	0.75
Age				
mean (SD)	73.1 (13.5)	73.2 (13.6)	73.0 (13.4)	0.7
Age groups				0.72
< 65 years	220 (15.8%)	113 (16.1%)	107 (15.6%)	
65-75 years	468 (33.7%)	229 (32.7%)	239 (34.7%)	
> 75 years	701 (50.5%)	359 (51.2%)	342 (49.7%)	
Nutritional assessment				
Mean body-mass index (kg/m2), mean (SD)	24.6 (5.3)	24.5 (5.2)	24.7 (5.4)	0.41
Mean body-weight (kg), median (IQR)	68.5 (58.4-81.5)	68.6 (58.4-81.4)	68.1 (58.8-81.5)	0.79
NRS 2002 Score				0.62
3 points	397 (28.6%)	196 (28.0%)	201 (29.2%)	
4 points	547 (39.4%)	272 (38.8%)	275 (40.0%)	
≥ 5 points	445 (32.0%)	233 (33.2%)	212 (30.8%)	
Weight loss, n (%)				1
≤ 5% in 3 months	679 (48.9%)	344 (49.1%)	335 (48.7%)	
> 5% in 3 months	226 (16.3%)	113 (16.1%)	113 (16.4%)	
> 5% in 2 months	186 (13.4%)	93 (13.3%)	93 (13.5%)	
> 5% in 1 month	298 (21.5%)	151 (21.5%)	147 (21.4%)	
Loss of appetite, n (%)	1242 (89.4%)	632 (90.2%)	610 (88.7%)	0.37
Food intake of normal requirement in the past week, n (%)				0.48
> 75%	130 (9.4%)	65 (9.3%)	65 (9.4%)	
50-75%	430 (31.0%)	204 (29.1%)	226 (32.8%)	
25-50%	581 (41.8%)	302 (43.1%)	279 (40.6%)	
< 25%	248 (17.9%)	130 (18.5%)	118 (17.2%)	
Severity of illness, n (%)				0.87
very mild	30 (2.2%)	16 (2.3%)	14 (2.0%)	
mild	924 (66.5%)	459 (65.5%)	465 (67.6%)	
moderate	418 (30.1%)	217 (31.0%)	201 (29.2%)	
severe	17 (1.2%)	9 (1.3%)	8 (1.2%)	
Laboratory measurements				
Admission Abumin level (g/L), mean (SD)	30.2 (6.7)	30.4 (6.9)	30.1 (6.4)	0.42
Admission CRP level (mg/L), median (IQR)	37 (9.4-117)	37 (8-110)	36 (10-120)	0.81
Main admission diagnosis				
Cardiovascular desease, n (%)	154 (11.1%)	83 (11.8%)	71 (10.3%)	0.37
Infection, n (%)	390 (28.1%)	208 (29.7%)	182 (26.5%)	0.18
Cancer, n (%)	287 (20.7%)	138 (19.7%)	149 (21.7%)	0.36
Pulmonary disease, n (%)	84 (6.0%)	48 (6.8%)	36 (5.2%)	0.21
Frailty, n (%)	128 (9.2%)	63 (9.0%)	65 (9.4%)	0.77
Other, n (%)	249 (17.9%)	118 (16.8%)	131 (19.0%)	0.28
Comorbidities				
Coronary heart disease, n (%)	391 (28.1%)	192 (27.4%)	199 (28.9%)	0.52
Congestive heart failure, n (%)	249 (17.9%)	126 (18.0%)	186 (18.3%)	0.96
Hypertension, n (%)	753 (54.2%)	380 (54.2%)	373 (54.2%)	1
Cerebrovascular disease, n (%)	105 (7.6%)	373 (54.2%)	53 (7.7%)	0.84
Peripheral arterial disease, n (%)	132 (9.5%)	75 (10.7%)	57 (8.3%)	0.13
Chronic kidney disease, n (%)	453 (32.6%)	223 (31.8%)	230 (33.4%)	0.52
Diabetes, n (%)	303 (21.8%)	156 (22.3%)	147 (21.4%)	0.69
COPD, n (%)	195 (14.0%)	96 (13.7%)	99 (14.4%)	0.71
Dementia, n (%)	57 (4.1%)	26 (3.7%)	31 (4.5%)	0.45
Malignant disease, n (%)	496 (35.7%)	248 (35.4%)	248 (36.0%)	0.99

Data sharing plan:

We intend to make data collected for the study, including deidentified individual participant data and a data dictionary defining each field in the set, available to others; Also, related documents will be available including the trial protocol and the statistical analysis plan. These data will be available with the publication of our main manuscript and all secondary projects as outlined in our trial protocol upon receipt of a letter of intention detailing the study hypothesis and statistical analysis plan. The steering committee of this trial will discuss all requests and decide based on the scientific rigor of the proposal whether data sharing is appropriate. All applicants are asked to sign a data access agreement. Please send any request to the principal investigator of this trial (Philipp.Schuetz@unibas.ch).